Cibc World Market Inc. lessened its holdings in shares of Organon & Co. (NYSE:OGN – Get Rating) by 30.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,030 shares of the company’s stock after selling 19,442 shares during the quarter. Cibc World Market Inc.’s holdings in Organon & Co. were worth $1,486,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of OGN. Investors Asset Management of Georgia Inc. GA ADV purchased a new position in Organon & Co. during the 2nd quarter valued at about $25,000. MCF Advisors LLC purchased a new position in Organon & Co. during the 1st quarter valued at about $29,000. Column Capital Advisors LLC lifted its holdings in shares of Organon & Co. by 112.0% during the 1st quarter. Column Capital Advisors LLC now owns 850 shares of the company’s stock valued at $30,000 after buying an additional 449 shares during the last quarter. SouthState Corp lifted its holdings in shares of Organon & Co. by 85.6% during the 1st quarter. SouthState Corp now owns 891 shares of the company’s stock valued at $31,000 after buying an additional 411 shares during the last quarter. Finally, ACG Wealth acquired a new stake in shares of Organon & Co. during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 76.28% of the company’s stock.
Organon & Co. Stock Performance
OGN opened at $24.40 on Friday. The business has a 50 day moving average price of $25.20 and a 200 day moving average price of $30.45. Organon & Co. has a twelve month low of $22.88 and a twelve month high of $39.47. The firm has a market cap of $6.21 billion, a P/E ratio of 6.16 and a beta of 0.87.
Organon & Co. Dividend Announcement
Analyst Ratings Changes
Several equities research analysts have recently issued reports on OGN shares. Morgan Stanley reduced their price target on Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating for the company in a report on Friday, November 4th. Piper Sandler upgraded Organon & Co. from a “neutral” rating to an “overweight” rating and reduced their price target for the company from $37.00 to $34.00 in a report on Tuesday, September 6th. Finally, Bank of America lowered Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 price target for the company. in a report on Friday, October 14th.
About Organon & Co.
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.